Patents by Inventor William B. Guggino

William B. Guggino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spiperone derivatives and methods of treating disorders
    Patent number: 8664237
    Abstract: Described herein are spiperone derivative compounds which have been found to be useful in methods of stimulating CaCC and treating disorders (or symptoms thereof) associated with CaCC including cystic fibrosis, wherein a compound of the invention is administered to a subject.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: March 4, 2014
    Assignee: The Johns Hopkins University
    Inventors: William B. Guggino, Erik M. Schwiebert, Lihua Liang
  • Compositions for treating cystic fibrosis
    Patent number: 8137962
    Abstract: The invention relates to compositions and methods of treating cystic fibrosis. More specifically, this invention relates to the use the AAV vectors and constructs to provide gene therapy to cystic fibrosis patients.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: March 20, 2012
    Assignees: University of Florida Research Foundation, The Johns Hopkins University
    Inventors: Terence R. Flotte, Jeffrey R. Sirninger, William B. Guggino, Liudmila Cebotaru, Christian Müller
  • SPIPERONE DERIVATIVES AND METHODS OF TREATING DISORDERS
    Publication number: 20120029005
    Abstract: Described herein are spiperone derivative compounds which have been found to be useful in methods of stimulating CaCC and treating disorders (or symptoms thereof) associated with CaCC including cystic fibrosis, wherein a compound of the invention is administered to a subject.
    Type: Application
    Filed: October 1, 2009
    Publication date: February 2, 2012
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: William B. Guggino, Erik M. Schwiebert, Lihua Liang
  • Generation of high titers of recombinant AAV vectors
    Patent number: 5658776
    Abstract: Adeno-associated virus (AAV) vectors may have utility for gene therapy but heretofore a significant obstacle has been the inability to generate sufficient quantifies of such recombinant vectors in amounts that would be clinically useful for human gene therapy application. Stable, helper-free AAV packaging cell lines have been elusive, mainly due to the activities of Rep protein, which down-regulates its own expression and reverses cellular immortalization. This invention provides packaging systems and processes for packaging AAV vectors that efficiently circumvent these problems by replacing the AAV p5 promoter with a heterologous promoter and that allow for substantially increased packaging efficiency.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 19, 1997
    Assignees: Targeted Genetics Corporation, Johns Hopkins University
    Inventors: Terence R. Flotte, Barrie J. Carter, William B. Guggino, Rikki Solow